Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

Aslanyan, M.G.; Kroeze, L.I.; Langemeijer, S.M.C.; Koorenhof-Scheele, T.N.; Massop, M.; Hoogen, P. van; ... ; Jansen, J.H. (2014)

Article / Letter to editor

• TET2 mutations
• Acute myeloid leukemia
• TET2 expression
• Prognosis

• All authors: Aslanyan, M.G.; Kroeze, L.I.; Langemeijer, S.M.C.; Koorenhof-Scheele, T.N.; Massop, M.; Hoogen, P. van; Stevens-Linders, E.; Locht, L.T. van de; Tonnissen, E.; Heijden, A. van der; Silva-Coelho, P. da; Cilloni, D.; Saglio, G.; Marie, J.P.; Tang, R.P.; Labar, B.; Amadori, S.; Muus, P.; Willemze, R.; Marijt, E.W.A.; Witte, T. de; Reijden, B.A. van der; Suciu, S.; Jansen, J.H.
• Date: 2014-08-31
• Journal: Annals of Hematology
• Volume: 93
• Issue: 8
• Pages: 1401 - 1412
• DOI: doi:10.1007/s00277-014-2055-7